TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18475181

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study: 17296463

Group type: EXPERIMENTAL
Intervention: Ofloxacin ER 400 mg QD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ofloxacin IR 200 mg BID
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Safety assessment (vital signs, ECGs, adverse events)
Number of subjects: 40
Study: 14732915

Group type: EXPERIMENTAL
Intervention: Systematic reviews of randomized trials in nephrology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11333294

Group type: EXPERIMENTAL
Intervention: 15 g of alcohol per day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 30 g of alcohol per day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (alcohol-free beverage)
Number of subjects: 51
Study: 9752963

Group type: EXPERIMENTAL
Intervention: Canal wall down tympanomastoidectomy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intact canal wall tympanomastoidectomy
Number of subjects: 12
Study: 7818063

Group type: EXPERIMENTAL
Intervention: Vecuronium administered by the Springfusor infusion device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vecuronium by intermittent bolus injection
Number of subjects: 20
Study: 3247518

Group type: EXPERIMENTAL
Intervention: Ketotifen (two 1‐mg capsules)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (identical capsules)
Number of subjects: 12
Study: 31288778

Group type: EXPERIMENTAL
Intervention: Pelvic plexus block (PPB) with 5 ml of 1% lidocaine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Conventional periprostatic nerve block (PNB) with 5 ml of 1% lidocaine
Number of subjects: 245

Group type: COMPARATOR
Intervention: Prostate capsule local anesthesia with 22 ml of 1% lidocaine (Control group)
Number of subjects: 245
Study: 27171347

Group type: EXPERIMENTAL
Intervention: Self-management of well-being (SMW) interventions
Number of subjects: 445
Study: 26425886

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) for 1 week
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 23317012

Group type: EXPERIMENTAL
Intervention: Consumption of juar tea (5 cups/day for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Consumption of barley tea (polyphenol-poor tea, 5 cups/day for 4 weeks)
Number of subjects: 20
Study: 22044856

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) with PI dose escalation
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Number of subjects: 183
Study: 19936408

Group type: EXPERIMENTAL
Intervention: Multiple session risk reduction intervention
Number of subjects: 392

Group type: COMPARATOR
Intervention: Single session risk reduction intervention
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Both conditions (multiple and single session)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Seropositive individuals
Number of subjects: 392
Study: 16498855

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 180 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 15306005

Group type: EXPERIMENTAL
Intervention: Fast rectal distension at 100 mL min(‐1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Slow rectal distension at 10 mL min(‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham distensions
Number of subjects: 14
Study: 11296014

Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine tartrate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of brimonidine and timolol
Number of subjects: 20
Study: 9032494

Group type: EXPERIMENTAL
Intervention: Ketotifen, 2 mg.day‐1
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 66
Study: 30354703

Group type: EXPERIMENTAL
Intervention: Morning dosing of antihypertensive agents
Number of subjects: 103

Group type: COMPARATOR
Intervention: Evening dosing of antihypertensive agents
Number of subjects: 103
Study: 27513534

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 897

Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 897
Study: 24245845

Group type: EXPERIMENTAL
Intervention: Daily self-weighing (DSW)
Number of subjects: 178
Study: 22203756

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m(2))
Number of subjects: 2693

Group type: EXPERIMENTAL
Intervention: dMMR tumors
Number of subjects: 2693
Study: 18650127

Group type: EXPERIMENTAL
Intervention: Manual titration
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Automatic titration
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pressure recommendation by automatic device
Number of subjects: 38
Study: 16680954

Group type: EXPERIMENTAL
Intervention: Acticoat (nanocrystalline silver dressing) applied once a day or every other two days depending on wound condition
Number of subjects: 98

Group type: COMPARATOR
Intervention: Silver sulfadiazine (SD-Ag)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Acticoat (nanocrystalline silver dressing)
Number of subjects: 98
Study: 15588342

Group type: EXPERIMENTAL
Intervention: Indinavir and efavirenz combination therapy
Number of subjects: 0
Study: 11841109

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) at 2Hz
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) at 100Hz
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 13
Study: 9623186

Group type: EXPERIMENTAL
Intervention: Plasma lactate concentration
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Temperature
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ESR
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clinical examination combined with standard laboratory tests
Number of subjects: 200
Study: 7888703

Group type: EXPERIMENTAL
Intervention: Anal submucosal injection of methotrexate (MXT) 50 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Parenteral injection of methotrexate (MXT) 50 mg
Number of subjects: 24
Study: 3209832

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel application
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo gel application
Number of subjects: 208
Study: 31856808

Group type: EXPERIMENTAL
Intervention: COMPASS-TC
Number of subjects: 2751

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2751
Study: 29016565

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 50000

Group type: COMPARATOR
Intervention: Annual fecal immunochemical test (FIT)
Number of subjects: 50000
Study: 25392187

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 23169068

Group type: EXPERIMENTAL
Intervention: Multilevel decompression and single-level fusion
Number of subjects: 207

Group type: COMPARATOR
Intervention: Multilevel decompression and multilevel fusion
Number of subjects: 207
Study: 21992621

Group type: EXPERIMENTAL
Intervention: Ankle-brachial index (ABI), measures of arterial stiffness, postprandial glucose, glycosylated hemoglobin, self-measured blood pressure, presence of comorbidity
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Follow-up after 18 months
Number of subjects: 2688
Study: 18326610

Group type: EXPERIMENTAL
Intervention: Early food supplementation
Number of subjects: 2853

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (MMs)
Number of subjects: 2853

Group type: COMPARATOR
Intervention: Usual food supplementation
Number of subjects: 2853

Group type: COMPARATOR
Intervention: 30 mg Fe + 400 microg folate
Number of subjects: 2853
Study: 17122221

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg melatonin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 14728607

Group type: EXPERIMENTAL
Intervention: CQ/AS
Number of subjects: 472

Group type: COMPARATOR
Intervention: CQ
Number of subjects: 472
Study: 11422888

Group type: EXPERIMENTAL
Intervention: Marathon runners
Number of subjects: 12
Study: 9245683

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral smoking cessation treatment plus vigorous exercise
Number of subjects: 281

Group type: COMPARATOR
Intervention: Cognitive-behavioral smoking cessation treatment plus contact control
Number of subjects: 281
Study: 8438811

Group type: EXPERIMENTAL
Intervention: ADTP vaccine
Number of subjects: 110

Group type: COMPARATOR
Intervention: WDTP vaccine
Number of subjects: 110
Study: 3125852

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg twice daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 31537090

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 31062351

Group type: EXPERIMENTAL
Intervention: Thermal Angel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypotherm X LG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: °M Warmer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buddy Lite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 28544230

Group type: EXPERIMENTAL
Intervention: Cardiac-diabetes self-management program incorporating telephone and text-messaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26224790

Group type: EXPERIMENTAL
Intervention: Antibacterial honey
Number of subjects: 371

Group type: COMPARATOR
Intervention: Control (Nasal mupirocin)
Number of subjects: 371
Study: 24355952

Group type: EXPERIMENTAL
Intervention: Probiotic ice-cream (100 ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Probiotic curd (100 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain ice-cream (100 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain curd (100 ml)
Number of subjects: 40
Study: 22164745

Group type: EXPERIMENTAL
Intervention: ISMN 40 mg
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: ISMN ‐ SR 60 mg
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo Vitamin C 100 mg
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: ISMN groups (both ISMN 40 mg and ISMN ‐ SR 60 mg)
Number of subjects: 156
Study: 19023893

Group type: EXPERIMENTAL
Intervention: Perturbation training (PERT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Strengthening group (STR)
Number of subjects: 19
Study: 16686585

Group type: EXPERIMENTAL
Intervention: Intensive management from clinical pharmacists and a diabetes care coordinator for 12 months
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group attended a single session led by pharmacists, followed by usual care
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 217
Study: 15656713

Group type: EXPERIMENTAL
Intervention: Krill oil 1-3 g per day (BMI-dependent)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fish oil (3 g daily containing 180 mg EPA and 120 mg DHA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 120
Study: 11355480

Group type: EXPERIMENTAL
Intervention: Patients with carcinoma of the larynx
Number of subjects: 7

Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 7
Study: 9140154

Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg + mg/h) continuous infusion for 72 hours
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole
Number of subjects: 333

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 333
Study: 8433137

Group type: EXPERIMENTAL
Intervention: PEG-SOD 10,000 U/kg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: PEG-SOD 5000 U/kg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: PEG-SOD 2000 U/kg
Number of subjects: 104
Study: 2885354

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 9
Study: 31289842

Group type: EXPERIMENTAL
Intervention: Mild Atopic Dermatitis
Number of subjects: 34313

Group type: EXPERIMENTAL
Intervention: Severe Atopic Dermatitis
Number of subjects: 34313
Study: 29357208

Group type: EXPERIMENTAL
Intervention: Vitamin D repletion
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 24254894

Group type: EXPERIMENTAL
Intervention: Recombinant thrombomodulin (ART‐123)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with overt DIC
Number of subjects: 0
Study: 24784545

Group type: EXPERIMENTAL
Intervention: Intervention schools (Students for Nutrition and eXercise program)
Number of subjects: 2997
Study: 22653986

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.3 mg) in exercise group (EX)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sublingual nitroglycerin (0.3 mg) in control group (CON)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.3 mg) in both groups
Number of subjects: 15
Study: 18814887

Group type: EXPERIMENTAL
Intervention: Rapid respiratory viral testing on admission
Number of subjects: 204

Group type: COMPARATOR
Intervention: Routine ED admission protocol
Number of subjects: 204
Study: 17329907

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 0
Study: 15333311

Group type: EXPERIMENTAL
Intervention: 12-week program of vigorous exercises integrated with lectures and discussions on diet, exercise, stress, and smoking
Number of subjects: 442

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 442
Study: 11839888

Group type: EXPERIMENTAL
Intervention: 6932 lead
Number of subjects: 336

Group type: COMPARATOR
Intervention: 6936 lead
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Both leads
Number of subjects: 336
Study: 9845613

Group type: EXPERIMENTAL
Intervention: Closed drainage system and first-generation cephalosporins
Number of subjects: 2755
Study: 7854929

Group type: EXPERIMENTAL
Intervention: IMED 980 infusion pump
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gemini infusion pump
Number of subjects: 26

Group type: COMPARATOR
Intervention: Gravity flow
Number of subjects: 26
Study: 2790405

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1008239

Group type: EXPERIMENTAL
Intervention: 15 mg/kg of 1,8% dextran in lactated Ringer's solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enflurane anaesthesia with preanaesthetic volume administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no dextran)
Number of subjects: 0
Study: 31029171

Group type: EXPERIMENTAL
Intervention: SAIA-SCALE intervention
Number of subjects: 36
Study: 27726925

Group type: EXPERIMENTAL
Intervention: HMB (3g·day‐1)
Number of subjects: 13
Study: 28247675

Group type: EXPERIMENTAL
Intervention: Vitaprost forte (rectal suppositories) and Vitaprost tablets
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard anti-inflammatory therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vitaprost treatment
Number of subjects: 90
Study: 23188563

Group type: EXPERIMENTAL
Intervention: Single-Port (SP) Cholecystectomy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Minilaparoscopic (ML) Cholecystectomy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional Laparoscopic (CL) Cholecystectomy
Number of subjects: 105
Study: 21881478

Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg once daily
Number of subjects: 157

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Etravirine
Number of subjects: 157
Study: 19367649

Group type: EXPERIMENTAL
Intervention: Silent thermotesting device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available thermotesting device
Number of subjects: 0
Study: 16769295

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15761556

Group type: EXPERIMENTAL
Intervention: NPH + R before breakfast and lunch and bedtime NPH (Group B)
Number of subjects: 53

Group type: COMPARATOR
Intervention: NPH + R before dinner and bedtime NPH (Group A)
Number of subjects: 53
Study: 11060833

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketorolac (Control)
Number of subjects: 0
Study: 9116434

Group type: EXPERIMENTAL
Intervention: NaHCO3 therapy (2 mmol/kg/day for 7 days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: NaCl therapy (2 mmol/kg/day for 7 days)
Number of subjects: 53
Study: 7506150

Group type: EXPERIMENTAL
Intervention: Nimesulide 200mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Paracetamol 500mg
Number of subjects: 39
Study: 2411246

Group type: EXPERIMENTAL
Intervention: Zimeldine (individualized doses to achieve plasma concentrations of 50 to 100 ng/mL)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Zimeldine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30236237

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg kg-1
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg kg-1
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 26754331

Group type: EXPERIMENTAL
Intervention: AndroForte 5 testosterone cream
Number of subjects: 16

Group type: COMPARATOR
Intervention: Testogel 1% testosterone gel
Number of subjects: 16
Study: 24590635

Group type: EXPERIMENTAL
Intervention: letrozole-lapatinib
Number of subjects: 92

Group type: COMPARATOR
Intervention: letrozole-placebo
Number of subjects: 92
Study: 21339763

Group type: EXPERIMENTAL
Intervention: Compact catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 30
Study: 16003272

Group type: EXPERIMENTAL
Intervention: Young African Americans (AAs)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Caucasians (Control)
Number of subjects: 122
Study: 12468746

Group type: EXPERIMENTAL
Intervention: Sherbrooke model arm (combined occupational and clinical interventions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occupational arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 9796053

Group type: EXPERIMENTAL
Intervention: DTPa-HBV/Hib vaccines co-administered with oral polio vaccine
Number of subjects: 269
Study: 7637191

Group type: COMPARATOR
Intervention: Vecuronium (0.03 mg.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.03 mg.kg‐1) after succinylcholine (1.0 mg.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.0 mg.kg‐1) followed by vecuronium (0.03 mg.kg‐1)
Number of subjects: 30
Study: 2793383

Group type: EXPERIMENTAL
Intervention: Acivicin (60 mg/m2/course, administered as a 72‐hr infusion)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Vinblastine (7.5 mg/m2/course, administered as a 120‐hr infusion)
Number of subjects: 66
Study: 350473

Group type: EXPERIMENTAL
Intervention: 800 mg aspirin and 64 mg caffeine (aspirin-caffeine)
Number of subjects: 140

Group type: COMPARATOR
Intervention: 650 mg aspirin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 30115103

Group type: EXPERIMENTAL
Intervention: Intravenous ivabradine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 27097690

Group type: EXPERIMENTAL
Intervention: Glidescope Videolaryngoscope (GVL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MCL)
Number of subjects: 80
Study: 25794628

Group type: EXPERIMENTAL
Intervention: Mogen clamp
Number of subjects: 274

Group type: COMPARATOR
Intervention: Gomco clamp
Number of subjects: 274
Study: 24102344

Group type: EXPERIMENTAL
Intervention: Standard therapy plus iloprost (administered for 10 days every 3 months)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard medical therapy (Control Group A)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Standard therapy plus iloprost
Number of subjects: 101
Study: 20498326

Group type: EXPERIMENTAL
Intervention: RDEA806 (400 mg twice a day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RDEA806 (600 mg once a day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RDEA806 (800 mg once a day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RDEA806 (1,000 mg once a day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 17852292

Group type: EXPERIMENTAL
Intervention: Qigong intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined group (intervention + control after crossover)
Number of subjects: 57
Study: 16552549

Group type: EXPERIMENTAL
Intervention: Patellar tendon with metal interference screw fixation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Hamstring tendon with titanium metal plate suspension and screw-washer postdistally
Number of subjects: 99

Group type: COMPARATOR
Intervention: Hamstring tendon group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 99
Study: 14634404

Group type: EXPERIMENTAL
Intervention: Rectal sensation test used during apical biopsy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group without rectal sensation test
Number of subjects: 30
Study: 10801252

Group type: EXPERIMENTAL
Intervention: Lanepitant (20, 60, 200, or 600 mg initial dose, followed by 10, 30, 100, or 300 mg twice a day)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Naproxen (375 mg twice a day)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 8835282

Group type: EXPERIMENTAL
Intervention: Caffeine (equivalent to a single cup of strong coffee)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 1333910

Group type: EXPERIMENTAL
Intervention: ADMOS alone
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: ADMOS plus CDDP
Number of subjects: 135

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 135